Drugs for Onchocerciasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 27)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Anticonvulsants |
|
Phase 4 |
|
|
|
2 |
|
Vitamins |
|
Phase 3 |
|
|
|
3 |
|
Levamisole |
Approved, Investigational, Vet_approved, Withdrawn |
Phase 2 |
|
14769-73-4 |
26879 |
Synonyms:
(-)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole
(-)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole
(-)-Tetramisole
(S)-(-)-Levamisole
(S)-(-)-Tetramisole
(S)-2,3,5,6-Tetrahydro-6-phenylimidazo[2,1-b]thiazole
Decaris
Dekaris
DL-Tetramisol
DL-Tetramisole
ERGAMISOL
Hydrochloride, levamisole
Ketrax
Lepuron
|
Levamisol
Levamisole
Levamisole hydrochloride
Levamisolum
Levomysol
Levotetramisole
Levovermax
L-Tetramisole
Phenyl imidothiazole
R-12564
Solaskil
TCMDC-125847
Totalon
Wormicid
|
|
4 |
|
Azithromycin |
Approved |
Phase 2 |
|
83905-01-5 |
447043 |
Synonyms:
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
Azadose
AZASITE
Azenil
Azifast
Azigram
Azimakrol
Azithramycine
AZITHROMYCIN
AZITHROMYCIN ANHYDROUS
Azithromycin dihydrate
AZITHROMYCIN HYDRATE
Azithromycin monohydrate
Azithromycin pfizer brand
Azithromycine
Azithromycinum
Azitrocin
Azitromicina
Azitromin
AZYTER
Azythromycin
Bayer brand OF azithromycin dihydrate
CLAMELLE
CP 62993
|
CP-62,993
CP-62993
Dihydrate, azithromycin
Funk brand OF azithromycin dihydrate
Goxal
Hemomycin
Lesvi brand OF azithromycin dihydrate
Mack brand OF azithromycin dihydrate
Monohydrate, azithromycin
Pfizer brand OF azithromycin
Pfizer brand OF azithromycin dihydrate
Pharmacia brand OF azithromycin dihydrate
Sumamed
SUNAMED
Toraseptol
Ultreon
Vinzam
Vita brand OF azithromycin dihydrate
XZ 405
XZ 450
XZ-450
Zentavion
Zithromax
Zitromax
Zmax
|
|
5 |
|
Rifampicin |
Approved |
Phase 2 |
|
13292-46-1 |
135512673 5381226 135900090 |
Synonyms:
2,15,17,23,27,29-Hexahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-{[(4-methylpiperazin-1-yl)imino]methyl}-6-oxo-8,30-dioxa-24-azatetracyclo[23.3.1.1,.0,]triaconta-1(28),2,4,9,19,21,23,25(29),26-nonaen-13-yl acetic acid
3-(((4-METHYL-1-PIPERAZINYL)IMINO)METHYL)RIFAMYCIN SV
Archidyn
BA-411661E
BA-41166E
Benemycin
EREMFAT
L-5103
L-5103 Lepetit
L-5103-LEPETIT
NIH-10782
NSC-113926
R/AMP
RAMP
Rfamipicin
RFP
Rifa
Rifadin
Rifadin IV
Rifadin®|rifampin
Rifadine
Rifagen
|
Rifaldazin
Rifaldazine
Rifaldin
RIFAMPICIN
Rifampicin SV
Rifampicina
Rifampicine
Rifampicinum
Rifampin
Rifamycin
RIFAMYCIN AMP
Rifaprodin
Rifoldin
Rifoldine
Riforal
Rimactan
Rimactane
Rimactin
Rimazid
Rofact
Tubocin
|
|
6 |
|
Ivermectin |
Approved, Investigational, Vet_approved |
Phase 2 |
|
70288-86-7 |
9812710 6427057 |
Synonyms:
CARDOMEC
CD5024
CD-5024
EQVALAN
Heartgard®|ivermectin B<sub>1a</sub>|MK-933|Sklice®|Soolantra®
HEARTGUARD
IVERMECTIN
IVERMECTIN COMPONENT B1A
Ivermectina
Ivermectine
|
Ivermectinum
IVOMEC
L 640471
L-640471
MECTIZAN
MK 933
MK-933
SKLICE
SOOLANTRA
STROMECTOL
|
|
7 |
|
Albendazole |
Approved, Vet_approved |
Phase 2 |
|
54965-21-8 |
2082 |
Synonyms:
(5-(Propylthio)-1H-benzimidazol-2-yl)carbamate methyl ester
(5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester
5-(Propylthio)-2-carbomethoxyaminobenzimidazole
Albendazol
Albendazole
Albendazole armstrong brand
Albendazole diba brand
Albendazole fustery brand
Albendazole hormona brand
Albendazole liferpal brand
Albendazole monohydrochloride
Albendazole noé-socopharm brand
Albendazole pfizer brand
Albendazole sanicoopa brand
Albendazole valdecasas brand
Albendazolum
Albendoral
Albenza
Andazol
Armstrong brand OF albendazole
Bendapar
Bilutac
Diba brand OF albendazole
Digezanol
Disthelm
Disthelm, mediamix V
Endoplus
Eskazole
Fustery brand OF albendazole
|
Gascop
Hormona brand OF albendazole
Liferpal brand OF albendazole
Lurdex
Mediamix V disthelm
Metiazol
Monohydrochloride, albendazole
Noé socopharm brand OF albendazole
Noé-socopharm brand OF albendazole
NSC-220008
O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate
O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamic acid
Pfizer brand OF albendazole
Proftril
RICOBENDAZOLE
RYCOBENDAZOLE
Sanicoopa brand OF albendazole
SK And F 62979
SK And F62979
SK And F-62979
SK&F 62979
SK&F-62979
SmithKline beecham brand OF albendazole
V Disthelm, mediamix
Valbazen
Valdecasas brand OF albendazole
ZENTAL
Zentel
|
|
8 |
|
Romidepsin |
Approved, Investigational |
Phase 2 |
|
128517-07-7 |
5352062 |
Synonyms:
ANTIBIOTIC FR 901228
CHROMADAX
DEPSIPEPTIDE
FK228
FK-228
FK228|FR901228|Istodax®
FR901228
|
FR-901228
ISTODAX
NSC-630176
ROMIDEPSIN
Romidepsina
Romidepsine
Romidepsinum
|
|
9 |
|
Emodepside |
Investigational, Vet_approved |
Phase 2 |
|
155030-63-0 |
|
Synonyms:
|
10 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
11 |
|
Antitubercular Agents |
|
Phase 2 |
|
|
|
12 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
13 |
|
Antimitotic Agents |
|
Phase 2 |
|
|
|
14 |
|
Antiprotozoal Agents |
|
Phase 2 |
|
|
|
15 |
|
Tubulin Modulators |
|
Phase 2 |
|
|
|
16 |
|
Sodium citrate |
Approved, Investigational |
|
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
17 |
|
Mebendazole |
Approved, Vet_approved |
|
|
31431-39-7 |
4030 |
Synonyms:
(5-Benzoyl-1H-benzimidazol-2-yl)-carbamate methyl ester
(5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester
Abello farmacia brand OF mebendazole
Anti worm
Anti-worm
Ardeypharm brand OF mebendazole
Bantenol
Banworm
Boots brand OF mebendazole
Boots threadworm treatment
Degort's brand OF mebendazole
Diba brand OF mebendazole
Elfar brand OF mebendazole
EMVERM
Esteve brand OF mebendazole
Healthypharm brand OF mebendazole
Janssen brand OF mebendazole
Leidapharm brand OF mebendazole
Lomper
Madicure
MBDZ
Mebendan
Mebendazol
Mebendazole
|
Mébendazole
MEBENDAZOLE POLYMORPH C
Mebendazolum
Mebenvet
Norgine brand OF mebendazole
NSC-184849
OVEX
Pfizer brand OF mebendazole
Pripsen mebendazole
R-17635
Sqworm
SSL Brand OF mebendazole
Streger brand OF mebendazole
Sufil
Surfont
Taxandria brand OF mebendazole
Tedec meiji brand OF mebendazole
Telmin
TELMINTIC
Vermicol
Vermidil
Vermin
Vermox
Wormkuur
|
|
18 |
|
Piperazine |
Approved, Vet_approved |
|
|
110-85-0 |
4837 |
Synonyms:
1,4 Diazacyclohexane
1,4 Piperazine
1,4-Diazacyclohexane
1,4-Piperazine
Diethylenediamine
Diethyleneimine
Fluphenazine dihydrochloride
Hexahydropyrazine
Piperazidine
Piperazin
Piperazina
Piperazine
Piperazine diacetate
Piperazine dihydrochloride
Piperazine hexahydrate
|
Piperazine hydrate
Piperazine hydrobromide
Piperazine hydrochloride
Piperazine monohydrochloride
Piperazine phosphate
Piperazine phosphate (1:1)
Piperazine phosphate anhydrous
Piperazine salt
Piperazine sulfate
Piperazine tartrate
Piperazine tartrate (1:1), (R-(r*,r*))-isomer
Piperazine tartrate, (R-(r*,r*))-isomer
Piperazinium oleate
Pripsen
Vermizine
|
|
19 |
|
Diethylcarbamazine |
Approved, Investigational, Vet_approved |
|
|
90-89-1 |
3052 |
Synonyms:
Aventis brand OF diethylcarbamazine citrate
Camin
Carbamazine
Carbilazine
Citrate, diethylcarbamazine
Diethyl carbamazine
Diethylcarbamazin
Diethylcarbamazine
Diéthylcarbamazine
Diethylcarbamazine citrate
Diethylcarbamazine citrate (1:1)
Diethylcarbamazine citrate (1:2)
Diethylcarbamazine L-tartrate (1:1)
Diethylcarbamazine maleate
|
Diethylcarbamazine monohydrochloride
Diethylcarbamazine phosphate (1:1)
Diethylcarbamazinum
Dietilcarbamazina
Ditrazine base
Ethodryl
Hetrazan
Loxuran
Maleate, diethylcarbamazine
Monohydrochloride, diethylcarbamazine
N,N-Diethyl-4-methyl-1-piperazinecarboxamide
N,N-Diethyl-4-methylpiperazine-1-carboxamide
Notezine
|
|
20 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
|
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
21 |
|
Calcium, Dietary |
|
|
|
|
|
22 |
|
Anticoagulants |
|
|
|
|
|
23 |
|
Citrate |
|
|
|
|
|
24 |
|
Piperazine citrate |
|
|
|
|
|
25 |
|
DMP 777 |
|
|
|
157341-41-8 |
|
26 |
|
Chelating Agents |
|
|
|
|
|
27 |
|
Calcium |
Nutraceutical |
|
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
Interventional clinical trials:
(show all 25)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
OAETREAT Extra Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy: a |
Completed |
NCT03852303 |
Phase 4 |
ivermectin |
2 |
Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy: A Randomized Clinical Trial |
Completed |
NCT03052998 |
Phase 4 |
Ivermectin |
3 |
Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis in the Volta Region, Ghana. |
Completed |
NCT02078024 |
Phase 3 |
IVM plus ALB;IVM |
4 |
Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis |
Completed |
NCT03238131 |
Phase 3 |
Ivermectin;Albendazole |
5 |
A Single-Dose, Ivermectin-Controlled, Double-Blind, Efficacy, Safety And Tolerability Study Of Orally Administered Moxidectin In Subjects Infected With Onchocerca Volvulus |
Completed |
NCT00790998 |
Phase 3 |
Moxidectin;Ivermectin |
6 |
A Randomized, Double Blind, Parallel Trial in the Democratic Republic of Congo (DRC) Comparing the Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Treatment of Onchocerciasis |
Recruiting |
NCT03876262 |
Phase 3 |
Moxidectin;Ivermectin |
7 |
A Randomized, Double Blind, Parallel Group Clinical Trial to Evaluate the Safety of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas |
Recruiting |
NCT04311671 |
Phase 3 |
Moxidectin;Ivermectin |
8 |
Randomized Clinical Trial, Double-blind, Dose-escalating of Drug Intensities, Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients |
Completed |
NCT04049630 |
Phase 2 |
LEV 1 mg/kg;LEV 1,5 mg/kg;LEV 2,5 mg/kg;Placebo |
9 |
A Randomized, Single-Ascending Dose, Ivermectin-Controlled, Double-Blind, Safety, Tolerability, Pharmacokinetic, and Efficacy Study Of Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection |
Completed |
NCT00300768 |
Phase 2 |
2 mg moxidectin;ivermectin 150 mcg/kg;4 mg moxidectin;8 mg moxidectin |
10 |
Trial of Rifampin and Azithromycin for Treatment of Endosymbiotic Bacteria (Wolbachia) in Onchocerca Volvulus in Guatemala |
Completed |
NCT00127504 |
Phase 2 |
Rifampin;Azithromycin |
11 |
Randomized Clinical Trial, Double-blind, Single-dose Drug and Escalating Infection Intensities, Evaluating the Safety and Efficacy of Moxidectin 2 mg, Ivermectin-controlled, in Loa Loa Microfilaremic Patients |
Recruiting |
NCT04049851 |
Phase 2 |
Moxidectin 2 MG Oral Tablet;Ivermectin 3Mg Tab;Placebo oral tablet |
12 |
A Phase-II, Randomised, Double-blind, Parallel-group Trial to Investigate Emodepside (BAY 44-4400) in Subjects With Onchocerca Volvulus Infection, Comprising: Part 1 to Investigate Safety, Tolerability, Pharmacodynamics, Pharmacokinetics and Dose-Response Relationship for Efficacy (Proof-of-Concept); Part 2 to Investigate Efficacy of Selected Doses, Safety, Tolerability and Pharmacokinetics |
Recruiting |
NCT05180461 |
Phase 2 |
emodepside;matching placebo of emodepside;ivermectin;matching placebo of ivermectin |
13 |
A Phase-II, Randomised, Double-blind, Parallel-group, Proof-of-concept Trial to Investigate ABBV-4083 Given for 7 or 14 Days or in Combination With Albendazole in Subjects With Onchocerca Volvulus Infection, Comprising: Part 1 to Investigate Safety, Tolerability, Efficacy for Dose-Ranging and Pharmacokinetics; Part 2 to Investigate Efficacy of Selected Doses, Safety, Tolerability and Pharmacokinetics |
Recruiting |
NCT04913610 |
Phase 2 |
ABBV-4083;Placebo for ABBV-4083;Albendazole;Placebo for Albendazole;Placebo for Ivermectin;Ivermectin |
14 |
Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis |
Active, not recruiting |
NCT04188301 |
Phase 2 |
IVM w/ ALB;Single dose of IDA;Three daily doses of IDA |
15 |
A Single-Center, Open-Label, Single-Dose Study To Assess The Pharmacokinetics, Safety, And Tolerability Of Moxidectin In Subjects Aged 4 To 11 Years ( >=12 kg) With Or Without Onchocerca Volvulus Infection |
Withdrawn |
NCT01035619 |
Phase 2 |
moxidectin |
16 |
An Open-label Study of the Pharmacokinetics and Safety of a Single Dose of Moxidectin Per Oral in Subjects Aged 4 to 17 Years With (or at Risk of) Onchocerciasis to Identify an Optimal Dose for Treatment of Children 4 to 11 Years |
Active, not recruiting |
NCT03962062 |
Phase 1 |
Moxidectin |
17 |
Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug |
Not yet recruiting |
NCT05084560 |
Phase 1 |
AWZ1066S;Placebo |
18 |
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District |
Unknown status |
NCT03653975 |
|
|
19 |
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia |
Completed |
NCT01905436 |
|
Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration |
20 |
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis |
Completed |
NCT01905423 |
|
Albendazole (annual);Diethylcarbamazine (annual);Albendazole (semiannual);Diethylcarbamazine (semiannual) |
21 |
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast |
Completed |
NCT02032043 |
|
Annual versus Semiannual Albendazole plus Ivermectin MDA |
22 |
Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas |
Completed |
NCT03131401 |
|
|
23 |
Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis |
Completed |
NCT03517462 |
|
Ivermectin 3Mg Tab |
24 |
Host Response to Infection and Treatment in the Filarial Diseases of Humans |
Recruiting |
NCT00001230 |
|
|
25 |
Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa |
Not yet recruiting |
NCT04035174 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Cochrane evidence based reviews: onchocerciasis
|